Hauke Busch, PhD
Director (Institute of Experimental Dermatology), W2 Professor
- University of Lübeck; Ratzeburger Allee 160, 23538 Lübeck, Germany
- +49-451-31018470
- +49-451-31018440
- hauke.busch@uni-luebeck.de
- https://www.systembiologie.uni-luebeck.de/
1992-1998 Study of Physics at the Darmstadt University of Technology, Germany and Trinity College Dublin, Ireland
1998 Diploma in Theoretical Physics, Darmstadt University of Technology
1999-2004 PhD thesis in theoretical Physics; Dr. rer. nat. on “The influence of spatiotemporally correlated noise on pattern formation”, Darmstadt University of Technology
2004-2008 Postdoctoral Researcher at the German Cancer Research Center, Division of Theoretical Bioinformatics, Prof. Eils, Heidelberg, Germany
2009-2013 Junior Research Fellow, Freiburg Institute of Advanced Studies, Freiburg, Germany
2016-present Professor for Medical Systems Biology at the University of Lübeck
2015-2016 Member of the Molecular Tumor Board, University Hospital, Freiburg
2015-2016 Member of the German Cancer Consortium Task Force “Whole Genome Sequencing”
2016-present Speaker of the High-Performance Computer Cluster Group, University of Lübeck
2016-present Head of Service Unit for Systems Biology, University of Lübeck
2017-2018 Member of the Steering Committee Excellence Cluster 306 “Inflammation at Interfaces”
2019-present Member of the Steering Committee Excellence Cluster 2167 “Precision Medicine in Inflammation”
2018-present Member of the Senate and Senate Committee for Medicine, University of Lübeck
2018-present Head of the Molecular Tumor Board, jointly with Head of Oncology and Head of Pathology, University Clinic Schleswig Holstein
2004-2007 Postdoc Scholarship from the Heidelberg BioMS Initiative
2008 Gold Medal in the International Genetically Engineered Machine competition with the Heidelberg iGEM Team
From 131 original publications; total citations 1,848; h-index: 23
- Busch H, Cmacho-Trullio D, Zbigniew R, Breihahn K, Angel P, Eils R, Szwabowski A. Gene network dynamics controlling keratinocyte migration. Mol Syst Biol 2008;4:199. [IF: 9.7]
- Mesecke S, Urlaub D, Busch H, Eils R, Watzl C. Integration of activating and inhibitory receptor signalling by regulated phosphorylation of Vav1 in immune cells. Sci Signal 2011;4:ra36. [IF: 7.5]
- Singh A, Nascimento JM, Kowar S, Busch H (equally contributing last author), Boerries M. Boolean approach to signalling pathway modelling in HGF-induced keratinocyte migration. Bioinformatics 2012;28:i495-i501.
[IF: 5.3] - Boerries M, Grahammer F, Eiselein S, Buck M, Meyer C, Goedel M, Bechtel W, Zschiedrich S, Pfeifer D, Laloë D, Arrondel C, Gonçalves S, Krüger M, Harvey SJ, Busch H (equally contributing last author), Dengjel J, Huber TB. Molecular fingerprinting of the podocyte reveals novel gene and protein regulatory networks. Kidney Int 2013;83:1052-64. [IF: 8.5]
- Herr R, Köhler M, Andrlová H, Weinberg F, Möller Y, Halbach S, Lutz L, Mastroianni J, Klose M, Bittermann N, Kowar S, Zeiser R, Olayioye MA, Lassmann S, Busch H, Boerries M. Brummer T. B-Raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cells. Cancer Res 2015;75:216-229 [IF: 9.1]
- Offermann B, Knauer S, Singh A, Fernández-Cachón ML, Klose M, Kowar S, Busch H (equally contributing senior author), Boerries M. Boolean modeling reveals the necessity of transcriptional regulation for bistability in PC12 cell differentiation. Front Genet 2016;7:44. [IF: 4.1]
- Jägle S, Busch H, Freihen V, Beyes S, Schrempp M, Boerries M, Hecht A. SNAIL1-mediated downregulation of FOXA proteins facilitates the inactivation of transcriptional enhancer elements at key epithelial genes in colorectal cancer cells. PLoS Genetics 2017;13:e1007109. [IF: 5.5]
- Krebs AM, Mitschke J, Lasierra Losada M, Schmalhofer O, Boerries M, Busch H, Boettcher M, Mougiakakos D, Reichardt W, Bronsert P, Brunton VG, Pilarsky C, Winkler TH, Brabletz S, Stemmler MP, Brabletz T. The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nat Cell Biol 2017;19:518-529. [IF: 20.1]
- Lipka DB, Witte T, Toth R, Yang J, Wiesenfarth M, Nöllke P, Fischer A, Brocks D, Gu Z, Park J, Strahm B, Wlodarski M, Yoshimi A, Claus R, Lübbert M, Busch H, Boerries M, Hartmann M, Schönung M, Kilik U, Langstein J, Wierzbinska JA, Pabst C, Garg S, Catalá A, De Moerloose B, Dworzak M, Hasle H, Locatelli F, Masetti R, Schmugge M, Smith O, Stary J, Ussowicz M, van den Heuvel-Eibrink MM, Assenov Y, Schlesner M, Niemeyer C, Flotho C, Plass C. RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia. Nat Commun 2017;8:2126. [IF: 12.4]
- Mathew NR, Baumgartner F, Braun L, O’Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD mutant leukemia cells. Nat Med 2018;24:282-29. [IF: 32.6]